Cost-effective analysis the value component of evidence-based medicine

Evidence-Based Eye Care

Volumn 1, Issue 3, 2000, Pages 177-181

  Brown, Melissa M ^a   Brown, Gary C ^a   Sharma, Sanjay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345827970     PISSN: 15258599     EISSN: 15364836     Source Type: Journal    
DOI: 10.1097/00132578-200004000-00024     Document Type: Article

References (19)

1. Branch Retinal Vein Occlusion Study Group. Argon laser for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
2. Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-721.
3. Gold ME, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
4. Brown MM, Brown GC, Sharma S, Garrett S. Evidence-based medicine, utilities and quality of life. CurrOpin Ophthalmol 1999;10:221-228.
5. Angell M. Patients’ preferences in randomized clinical trials. N Engl J Med 1984;310:1385-1387.
6. Kassirer JP. Incorporating patients’ preferences into medical decisions. N Engl J Med 1994;330: 1895-1896.
7. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14: an index of functional impairment in patients with cataract. Arch Ophthalmol 1994;112:630-638.
8. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992; 30:473-483.
9. Redelmeier DA, Detsky AS. A clinician’s guide to utility measurement. In: Bergus GR, Cantor SB, eds. Primary Care: Clinics in Office Practice. Philadelphia, PA: WB Saunders, 1995:271-280.
10. Sonnenberg FA, Beck JR Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
11. Damodaran A. Corporate Finance: Theory and Practice. New York, John Wiley & Sons, 1997:37-65.
12. Brown GC, Brown MM, Sharma S, Tasman W, Brown H. Cost-effectiveness of treatment for threshold retinopathy of prematurity. Pediatrics (in press).
13. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481.
14. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993: 111:1200-1209.
15. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997; 115: 741-747.
16. Vital Statistics of United States, 1994. Preprint of Volume II, Mortality, Part A, Section 6. Hyattsville, MD: US Department of Health and Human Services; 1998. DHHS data Publication No. (PHS) 98-1104.
17. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999; 92:474-511.
18. Davis JB. Medical Fees in the United States: Nationwide Charges for Medicine, Surgery, Laboratory, Radiology and Allied Health Services. Los Angeles: PracticeMan-agement Information Corporation; 1999.
19. Data™ 3.5 for Healthcare User’s Manual. William-stown, MA: Treeage Software, Inc.; 1999.